Eleven Biotherapeutics’ Isunakinra Misses Primary Endpoint in Phase 3

Eleven Biotherapeutics’ lead investigational drug isunakinra has missed its mark in a Phase 3 trial in severe allergic conjunctivitis, leading the company to move away from pursuing the indication.

The candidate failed to meet the primary endpoint of reduced eye itching, with no statistically significant difference between the treatment and placebo.

The company says its priority will shift to submitting an IND for another candidate, EBI-031, in diabetic macular edema during the first half of this year.